Valproic acid enhances Oct4 promoter activity through PI3K/Akt/mTOR pathway activated nuclear receptors

Molecular and Cellular Endocrinology

Volumn 383, Issue 1-2, 2014, Pages 147-158

  Teng, Han Fang ^a   Li, Pei Ning ^a   Hou, Duen Ren ^a   Liu, Sin Wei ^a   Lin, Cheng Tao ^a   Loo, Moo Rung ^a   Kao, Chien Han ^a   Lin, Kwang Huei ^b   Chen, Shen Liang ^a  

^a NATIONAL CENTRAL UNIVERSITY   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Akt; IPSC; Muscle; Nuclear receptor; Oct4; VPA

Indexed keywords

2 BUTYLHEXENOIC ACID; 2 ETHYLVALERIC ACID; 2 HEXANYLOCTANOIC ACID; 2 PENTYLHEPTANOIC ACID; 2 PENTYLHEXANOIC ACID; CELL NUCLEUS RECEPTOR; CHICKEN OVALBUMIN UPSTREAM PROMOTER TRANSCRIPTION FACTOR 2; DIISOPROPYLACETIC ACID; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; OCTAMER TRANSCRIPTION FACTOR 4; PHOSPHATIDYLINOSITOL 3 KINASE; PROPYLISOPROPYLACETIC ACID; PROTEIN KINASE B; PROTEIN TR2; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; VALPROIC ACID; VALPROIC ACID DERIVATIVE;

ANIMAL CELL; ARTICLE; DRUG STRUCTURE; EMBRYO; EMBRYONIC STEM CELL; GENE ACTIVATION; GENE SILENCING; HORMONE RESPONSIVE ELEMENT; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; MOUSE; NONHUMAN; OCT4 GENE; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROMOTER REGION; TRANSCRIPTION REGULATION;

AKT; IPSC; MUSCLE; NUCLEAR RECEPTOR; OCT4; VPA;

ANIMALS; BASE SEQUENCE; CELL DIFFERENTIATION; CELL LINE, TUMOR; COUP TRANSCRIPTION FACTOR II; GENE EXPRESSION REGULATION; INDUCED PLURIPOTENT STEM CELLS; MICE; MOLECULAR SEQUENCE DATA; MUSCLE CELLS; NUCLEAR RECEPTOR SUBFAMILY 2, GROUP C, MEMBER 1; NUCLEAR REPROGRAMMING; OCTAMER TRANSCRIPTION FACTOR-3; PHOSPHATIDYLINOSITOL 3-KINASES; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; VALPROIC ACID;

EID: 84891894692     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2013.12.008     Document Type: Article

References (58)

1. Bojic U., Elmazar M.M., Hauck R.S., Nau H. Further branching of valproate-related carboxylic acids reduces the teratogenic activity, but not the anticonvulsant effect. Chem. Res. Toxicol. 1996, 9:866-870.
2. Braissant O., Wahli W. Differential expression of peroxisome proliferator-activated receptor-alpha, -beta, and -gamma during rat embryonic development. Endocrinology 1998, 139:2748-2754.
3. Bug G., Gul H., Schwarz K., Pfeifer H., Kampfmann M., Zheng X., Beissert T., Boehrer S., Hoelzer D., Ottmann O.G., et al. Valproic acid stimulates proliferation and self-renewal of hematopoietic stem cells. Cancer Res. 2005, 65:2537-2541.
4. Chang J.H., Lin K.H., Shih C.H., Chang Y.J., Chi H.C., Chen S.L. Myogenic basic helix-loop-helix proteins regulate the expression of peroxisomal proliferator activated receptor-gamma coactivator-1alpha. Endocrinology 2006, 147:3093-3106.
5. Chen G., Huang L.D., Jiang Y.M., Manji H.K. The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. J. Neurochem. 1999, 72:1327-1330.
6. Chuang Y.S., Huang W.H., Park S.W., Persaud S.D., Hung C.H., Ho P.C., Wei L.N. Promyelocytic leukemia protein in retinoic acid-induced chromatin remodeling of Oct4 gene promoter. Stem Cells 2011, 29:660-669.
7. Chung S.Y., Huang W.C., Su C.W., Lee K.W., Chi H.C., Lin C.T., Chen S.T., Huang K.M., Tsai M.S., Yu H.P., et al. FoxO6 and PGC-1alpha form a regulatory loop in myogenic cells. Biosci. Rep. 2013, 33.
8. Dressel U., Allen T.L., Pippal J.B., Rohde P.R., Lau P., Muscat G.E. The peroxisome proliferator-activated receptor beta/delta agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells. Mol. Endocrinol. 2003, 17:2477-2493.
9. Frediani F. Anticonvulsant drugs in primary headaches prophylaxis. Neurol. Sci. 2004, 25(Suppl 3):S161-S166.
10. Fuhrmann G., Chung A.C., Jackson K.J., Hummelke G., Baniahmad A., Sutter J., Sylvester I., Scholer H.R., Cooney A.J. Mouse germline restriction of Oct4 expression by germ cell nuclear factor. Dev. Cell 2001, 1:377-387.
11. Goodwin F.K., Fireman B., Simon G.E., Hunkeler E.M., Lee J., Revicki D. Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA 2003, 290:1467-1473.
12. Gottlicher M., Minucci S., Zhu P., Kramer O.H., Schimpf A., Giavara S., Sleeman J.P., Lo Coco F., Nervi C., Pelicci P.G., et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 2001, 20:6969-6978.
13. Graziani G., Tentori L., Portarena I., Vergati M., Navarra P. Valproic acid increases the stimulatory effect of estrogens on proliferation of human endometrial adenocarcinoma cells. Endocrinology 2003, 144:2822-2828.
14. Gupta P., Ho P.C., Huq M.M., Ha S.G., Park S.W., Khan A.A., Tsai N.P., Wei L.N. Retinoic acid-stimulated sequential phosphorylation, PML recruitment, and SUMOylation of nuclear receptor TR2 to suppress Oct4 expression. Proc. Natl. Acad. Sci. USA 2008, 105:11424-11429.
15. Gurpur P.B., Liu J., Burkin D.J., Kaufman S.J. Valproic acid activates the PI3K/Akt/mTOR pathway in muscle and ameliorates pathology in a mouse model of Duchenne muscular dystrophy. Am. J. Pathol. 2009, 174:999-1008.
16. Gurvich N., Tsygankova O.M., Meinkoth J.L., Klein P.S. Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Cancer Res. 2004, 64:1079-1086.
17. Huangfu D., Maehr R., Guo W., Eijkelenboom A., Snitow M., Chen A.E., Melton D.A. Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds. Nat. Biotechnol. 2008, 26:795-797.
18. Huangfu D., Osafune K., Maehr R., Guo W., Eijkelenboom A., Chen S., Muhlestein W., Melton D.A. Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. Nat. Biotechnol. 2008, 26:1269-1275.
19. Jeong Y., Mangelsdorf D.J. Nuclear receptor regulation of stemness and stem cell differentiation. Exp. Mol. Med. 2009, 41:525-537.
20. Jung G.A., Yoon J.Y., Moon B.S., Yang D.H., Kim H.Y., Lee S.H., Bryja V., Arenas E., Choi K.Y. Valproic acid induces differentiation and inhibition of proliferation in neural progenitor cells via the beta-catenin-Ras-ERK-p21Cip/WAF1 pathway. BMC Cell Biol. 2008, 9:66.
21. Jung J.W., Park S.B., Lee S.J., Seo M.S., Trosko J.E., Kang K.S. Metformin represses self-renewal of the human breast carcinoma stem cells via inhibition of estrogen receptor-mediated OCT4 expression. PloS One 2011, 6:e28068.
22. Lampen A., Grimaldi P.A., Nau H. Modulation of peroxisome proliferator-activated receptor delta activity affects neural cell adhesion molecule and polysialyltransferase ST8SiaIV induction by teratogenic valproic acid analogs in F9 cell differentiation. Mol. Pharmacol. 2005, 68:193-203.
23. Lang K.C., Lin I.H., Teng H.F., Huang Y.C., Li C.L., Tang K.T., Chen S.L. Simultaneous overexpression of Oct4 and Nanog abrogates terminal myogenesis. Am. J. Physiol. Cell Physiol. 2009, 297:C43-C54.
24. Li W., Ding S. Small molecules that modulate embryonic stem cell fate and somatic cell reprogramming. Trends Pharmacol. Sci. 2009, 31:36-45.
25. Lowry W.E., Plath K. The many ways to make an iPS cell. Nat. Biotechnol. 2008, 26:1246-1248.
26. Lowry W.E., Richter L., Yachechko R., Pyle A.D., Tchieu J., Sridharan R., Clark A.T., Plath K. Generation of human induced pluripotent stem cells from dermal fibroblasts. Proc. Natl. Acad. Sci. USA 2008, 105:2883-2888.
27. Mauro A. Satellite cell of skeletal muscle fibers. J. Biophys. Biochem. Cytol. 1961, 9:493-495.
28. Muscat G.E., Dressel U. Cardiovascular disease and PPARdelta: targeting the risk factors. Curr. Opin. Invest. Drugs 2005, 6:887-894.
29. Okazawa H., Okamoto K., Ishino F., Ishino-Kaneko T., Takeda S., Toyoda Y., Muramatsu M., Hamada H. The oct3 gene, a gene for an embryonic transcription factor, is controlled by a retinoic acid repressible enhancer. EMBO J. 1991, 10:2997-3005.
30. Okita K., Ichisaka T., Yamanaka S. Generation of germline-competent induced pluripotent stem cells. Nature 2007, 448:313-317.
31. Okita K., Nakagawa M., Hyenjong H., Ichisaka T., Yamanaka S. Generation of mouse induced pluripotent stem cells without viral vectors. Science 2008, 322:949-953.
32. Park S.W., Hu X., Gupta P., Lin Y.P., Ha S.G., Wei L.N. SUMOylation of Tr2 orphan receptor involves Pml and fine-tunes Oct4 expression in stem cells. Nat. Struct. Mol. Biol. 2007, 14:68-75.
33. Park S., Song J., Joe C.O., Shin I. Akt stabilizes estrogen receptor alpha with the concomitant reduction in its transcriptional activity. Cell. Signal. 2008, 20:1368-1374.
34. Pasha Z., Haider H., Ashraf M. Efficient non-viral reprogramming of myoblasts to stemness with a single small molecule to generate cardiac progenitor cells. PloS One 2011, 6:e23667.
35. Pekarsky Y., Hallas C., Palamarchuk A., Koval A., Bullrich F., Hirata Y., Bichi R., Letofsky J., Croce C.M. Akt phosphorylates and regulates the orphan nuclear receptor Nur77. Proc. Natl. Acad. Sci. USA 2001, 98:3690-3694.
36. Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35years of clinical experience. CNS Drugs 2002, 16:695-714.
37. Pikarsky E., Sharir H., Ben-Shushan E., Bergman Y. Retinoic acid represses Oct-3/4 gene expression through several retinoic acid-responsive elements located in the promoter-enhancer region. Mol. Cell. Biol. 1994, 14:1026-1038.
38. Rao M.S., Civin C.I. How many human embryonic stem cell lines are sufficient? A U.S. Perspective. Stem Cells 2006.
39. Schoorlemmer J., van Puijenbroek A., van Den Eijnden M., Jonk L., Pals C., Kruijer W. Characterization of a negative retinoic acid response element in the murine Oct4 promoter. Mol. Cell. Biol. 1994, 14:1122-1136.
40. Seale P., Rudnicki M.A. A new look at the origin, function, and "stem-cell" status of muscle satellite cells. Dev. Biol. 2000, 218:115-124.
41. Shi Y., Desponts C., Do J.T., Hahm H.S., Scholer H.R., Ding S. Induction of pluripotent stem cells from mouse embryonic fibroblasts by Oct4 and Klf4 with small-molecule compounds. Cell Stem Cell 2008, 3:568-574.
42. Shi Y., Do J.T., Desponts C., Hahm H.S., Scholer H.R., Ding S. A combined chemical and genetic approach for the generation of induced pluripotent stem cells. Cell Stem Cell 2008, 2:525-528.
43. Shimshoni J.A., Bialer M., Wlodarczyk B., Finnell R.H., Yagen B. Potent anticonvulsant urea derivatives of constitutional isomers of valproic acid. J. Med. Chem. 2007, 50:6419-6427.
44. Shimshoni J.A., Dalton E.C., Jenkins A., Eyal S., Ewan K., Williams R.S., Pessah N., Yagen B., Harwood A.J., Bialer M. The effects of central nervous system-active valproic acid constitutional isomers, cyclopropyl analogs, and amide derivatives on neuronal growth cone behavior. Mol. Pharmacol. 2007, 71:884-892.
45. Shyr C.R., Kang H.Y., Tsai M.Y., Liu N.C., Ku P.Y., Huang K.E., Chang C. Roles of testicular orphan nuclear receptors 2 and 4 in early embryonic development and embryonic stem cells. Endocrinology 2009, 150:2454-2462.
46. Stadtfeld M., Nagaya M., Utikal J., Weir G., Hochedlinger K. Induced pluripotent stem cells generated without viral integration. Science 2008, 322:945-949.
47. Tajbakhsh S. Skeletal muscle stem and progenitor cells: reconciling genetics and lineage. Exp. Cell Res. 2005, 306:364-372.
48. Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126:663-676.
49. Takahashi K., Tanabe K., Ohnuki M., Narita M., Ichisaka T., Tomoda K., Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131:861-872.
50. Teng H.F., Kuo Y.L., Loo M.R., Li C.L., Chu T.W., Suo H., Liu H.S., Lin K.H., Chen S.L. Valproic acid enhances Oct4 promoter activity in myogenic cells. J. Cell. Biochem. 2010, 110:995-1004.
51. Thomson J.A., Itskovitz-Eldor J., Shapiro S.S., Waknitz M.A., Swiergiel J.J., Marshall V.S., Jones J.M. Embryonic stem cell lines derived from human blastocysts. Science 1998, 282:1145-1147.
52. Werling U., Siehler S., Litfin M., Nau H., Gottlicher M. Induction of differentiation in F9 cells and activation of peroxisome proliferator-activated receptor delta by valproic acid and its teratogenic derivatives. Mol. Pharmacol. 2001, 59:1269-1276.
53. Wernig M., Meissner A., Foreman R., Brambrink T., Ku M., Hochedlinger K., Bernstein B.E., Jaenisch R. In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature 2007, 448:318-324.
54. Xie C.Q., Jeong Y., Fu M., Bookout A.L., Garcia-Barrio M.T., Sun T., Kim B.H., Xie Y., Root S., Zhang J., et al. Expression profiling of nuclear receptors in human and mouse embryonic stem cells. Mol. Endocrinol. 2009, 23:724-733.
55. Yang H.M., Do H.J., Kim D.K., Park J.K., Chang W.K., Chung H.M., Choi S.Y., Kim J.H. Transcriptional regulation of human Oct4 by steroidogenic factor-1. J. Cell. Biochem. 2007, 101:1198-1209.
56. Yeom Y.I., Fuhrmann G., Ovitt C.E., Brehm A., Ohbo K., Gross M., Hubner K., Scholer H.R. Germline regulatory element of Oct-4 specific for the totipotent cycle of embryonal cells. Development 1996, 122:881-894.
57. Yu J., Vodyanik M.A., Smuga-Otto K., Antosiewicz-Bourget J., Frane J.L., Tian S., Nie J., Jonsdottir G.A., Ruotti V., Stewart R., et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007.
58. Zhu S., Li W., Zhou H., Wei W., Ambasudhan R., Lin T., Kim J., Zhang K., Ding S. Reprogramming of human primary somatic cells by OCT4 and chemical compounds. Cell Stem Cell 2010, 7:651-655.